Last $26.87 USD
Change Today +0.30 / 1.13%
Volume 479.4K
MR On Other Exchanges
Symbol
Exchange
New York
Singapore
Mexico
Frankfurt
As of 5:15 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

mindray medical intl ltd-adr (MR) Snapshot

Open
$26.40
Previous Close
$26.57
Day High
$27.10
Day Low
$26.30
52 Week High
01/13/14 - $40.89
52 Week Low
12/24/14 - $26.30
Market Cap
3.2B
Average Volume 10 Days
869.9K
EPS TTM
$1.98
Shares Outstanding
87.8M
EX-Date
03/12/14
P/E TM
13.6x
Dividend
$0.50
Dividend Yield
1.86%
Current Stock Chart for MINDRAY MEDICAL INTL LTD-ADR (MR)

mindray medical intl ltd-adr (MR) Related Businessweek News

View More BusinessWeek News

mindray medical intl ltd-adr (MR) Details

Mindray Medical International Limited develops, manufactures, and markets medical devices worldwide. The company operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. The Patient Monitoring and Life Support Products segment offers monitoring devices that track the physiological parameters of patients, such as heart rate, blood pressure, respiration, and temperature. Its products include single and multiple-parameter monitors; mobile and portable multifunction monitors; central stations that can collect and display multiple patient data on a single screen; electro-cardiogram monitoring devices; and veterinary monitoring devices. This segment also provides anesthesia machines; defibrillators; surgical equipment, including surgical beds, and surgical lights ceiling pendants; syringes and infusion pumps; and ventilators. The In-Vitro Diagnostic Products segment provides data and analysis on blood, urine, and other bodily fluid samples for clinical diagnosis and treatment; and in-vitro diagnostic products for laboratories, clinics, and hospitals to perform analysis to detect and quantify substances in patient samples. Its product portfolio consists of hematology analysis products, biochemistry analysis products, immunoassay products, coagulation analysis products, urine sediment analysis products, and microbiology analysis products; and reagents used in in-vitro diagnostic products. The Medical Imaging Systems segment offers ultrasound systems used in medical fields, such as urology, gynecology, obstetrics, and cardiology; digital radiography systems; and magnetic resonance imaging systems. The company also provides orthopedic products, endoscope devices, and healthcare IT solutions. Its markets and sells its products through distributors, as well as directly to hospitals and government agencies. The company was founded in 1991 and is headquartered in Shenzhen, The People’s Republic of China.

8,300 Employees
Last Reported Date: 11/3/14
Founded in 1991

mindray medical intl ltd-adr (MR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mindray medical intl ltd-adr (MR) Key Developments

Mindray Medical International Limited, Annual General Meeting, Dec 10, 2014

Mindray Medical International Limited, Annual General Meeting, Dec 10, 2014., at 11:00 China Standard Time. Location: Company's Hong Kong office, FLAT/RM 15-16 BLK 1 11/F. Agenda: To consider the re-election of directors; and to consider the ratification of the appointment of PricewaterhouseCoopers as the independent registered public accounting firm for the fiscal year ending December 31, 2014.

Mindray Medical International Limited Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Full Year 2014

Mindray Medical International Limited announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net revenues of $324,636,000 from $296,318,000 a year ago. Income from operations was $43,398,000 against $50,536,000 a year ago. Income before income taxes and non-controlling interests was $52,097,000 against $59,161,000 a year ago. Net income attributable to the company was $46,043,000 or $0.39 per basin and diluted share against $30,064,000 or $0.25 per basin and diluted share a year ago. Net cash provided by operating activities was $85,524,000 against $67,097,000 a year ago. Capital expenditures were $28,057,000 against $26,939,000 a year ago. Non-GAAP net income attributable to the company was $56,157,000 or $0.47 per diluted share against $57,412,000 or $0.47 per diluted share a year ago. Non-GAAP operating income was $54,434,000 against $57,433,000 a year ago. Earnings before interest and taxes (EBIT) were $42,704,000 against $49,707,000 a year ago. Earnings before interest, taxes, depreciation, and amortization (EBITDA) were $57,517, 000 against $64,663,000 a year ago. For the nine months, the company reported net revenues of $923,859,000 against $845,572,000 a year ago. Income from operations was $139,108,000 against $156,254,000 a year ago. Income before income taxes and non-controlling interests was $164,172,000 against $179,162,000 a year ago. Net income attributable to the company was $141,299,000 or $1.19 per diluted share against $149,538000 or $1.24 per diluted share a year ago. Net cash provided by operating activities was $189,789,000 against $185,722,000 a year ago. Capital expenditures were $79,108,000 against $67,179,000 a year ago. Non-GAAP net income attributable to the company was $168,430,000 or $1.42 per diluted share against $190,220,000 or $1.57 per diluted share a year ago. Non-GAAP operating income was $168,380,000 against $176,900,000 a year ago. Earnings before interest and taxes (EBIT) were $137,137,000 against $153,206,000 a year ago. Earnings before interest, taxes, depreciation, and amortization (EBITDA) were $180,428,000 against $193,369,000 a year ago. The company provided earnings guidance for the full year 2014. The company now expects net revenues to grow below 10% over its full year 2013 net revenues. Management now also anticipates its full year 2014 non-GAAP net income to decrease by a single-digit percentage over its full year 2013 non-GAAP net income. This guidance excludes the tax benefits related to the nationwide key software enterprise status and assumes a corporate income tax rate of 15% applicable to the Shenzhen subsidiary. The company expects its capital expenditure for full year 2014 to be around $110 million.

Mindray Medical International Limited to Report Q3, 2014 Results on Nov 03, 2014

Mindray Medical International Limited announced that they will report Q3, 2014 results at 5:00 PM, China Standard Time on Nov 03, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MR:US $26.87 USD +0.30

MR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Analogic Corp $86.43 USD +0.32
Hutchinson Technology Inc $3.60 USD 0.00
Masimo Corp $26.60 USD +0.04
Nihon Kohden Corp ¥6,140 JPY +110.00
OSI Systems Inc $71.75 USD +0.12
View Industry Companies
 

Industry Analysis

MR

Industry Average

Valuation MR Industry Range
Price/Earnings 14.7x
Price/Sales 2.4x
Price/Book 2.1x
Price/Cash Flow 14.6x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MINDRAY MEDICAL INTL LTD-ADR, please visit www.mindray.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.